Intec Pharma Ltd. (NTEC)
(Delayed Data from NSDQ)
$6.24 USD
+0.02 (0.32%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.24 USD
+0.02 (0.32%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Intec Pharma Ltd. (NTEC) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Intec Pharma Ltd. (NTEC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Implied Volatility Surging for Intec Pharma (NTEC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Intec Pharma (NTEC) stock based on the movements in the options market lately.
New Strong Buy Stocks for May 4th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Implied Volatility Surging for Intec Pharma (NTEC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Intec Pharma (NTEC) stock based on the movements in the options market lately.
Can European Expansion Aid Canopy Growth (CGC) Q1 Earnings?
by Zacks Equity Research
Canopy Growth's (CGC) recent acquisition of European companies will help it expand its production footprint into one of the most promising international regions.
ArQule (ARQL) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.
Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More
by Zacks Equity Research
Key highlights of the past week are regulatory and pipeline developments along with research collaboration deals.
Intec Pharma (NTEC) Catches Eye: Stock Adds 9.8% in Session
by Zacks Equity Research
Intec Pharma Ltd. (NTEC) moved big last session, as its shares rose more than 9% on the day.